Meet our Team
Scientific advisory board
RHI CSO
DR. HINRICH STAECKER
MD. PHD
RHI Chief Scientific Officer
and University of Kansas Medical Leader and Visionary. Dr. Staecker created the first and only gene therapy for hearing loss approved for human clinical trials (Novartis CGF166).
Founding Scientific Advisor
DR. XUE ZHONG LIU
MD. PHD
RHI Scientific Advisor and decorated Surgeon at the University of Miami. Dr. Liu’s expertise in identifying the genetic causes of hearing loss is unparalleled; as one of the top NIH-funded Otolaryngologists.
DR. JEFFREY HOLT
PHD
RHI Scientific Advisor from Boston Children’s Hospital at Harvard’s Medical School. Dr. Holt brings expertise in developing vector constructs for the delivery of gene therapies to the inner ear.
Dr. Athanasia Warnecke
MD. PHD
RHI Scientific Advisor from Hannover Medical School in Germany. Dr. Warnecke is a Physician / Surgeon / Researcher with expertise in developing novel gene therapy platforms and presenting regulatory approval packages to the Paul Ehrlich Institute (Germany’s FDA).
Business Advisors
DR. LEE GOLDEN
An MD Clinical Trial design and Drug Development Specialist bringing over 20+ years of experience in all phases of drug development. Currently the Head of Global Clinical Development at PTC Therapeutics
ANDREW KOOPMAN
Investor Relations and Business Development of more than 30 years in the Biotechnology and Biomedical industries.
